. Author manuscript; available in PMC: 2014 Jul 1.

Published in final edited form as: Leukemia. 2013 Aug 27;28(1):34–43. doi: 10.1038/leu.2013.248

Table 1.

Next-generation sequencing studies of clonal evolution in hematologic malignancies

Disease	Methodology	Number of cases	Insights
AML³⁹	WGS, followed by targeted deep sequencing	8	Relapse after chemotherapy is associated with clonal evolution and acquisition of new mutations
Secondary AML⁴⁶	WGS, followed by targeted deep sequencing	7	Secondary AML clones are often evolved progeny of MDS clones
Multiple Myeloma⁴⁷	WES	1	Clonal shifts occur along the history of the disease
Multiple Myeloma¹¹⁸	WES	1	Clonal shifts occur along the history of the disease
CLL⁷⁶	WGS, followed by targeted deep sequencing	3	Different patterns of evolution evident through cycles of therapy
CLL⁴⁰	WES	149 (18 longitudinal samples)	Subclonal drivers can anticipate clonal evolution and impact outcome
Essential thrombocytosis¹¹⁵	Single cell WES	1	ET is monoclonal in origin
Follicular Lymphoma¹¹⁹	WES	8	Early and late drivers identified